HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Desonide (Desowen)

A nonfluorinated corticosteroid anti-inflammatory agent used topically for DERMATOSES.

Also Known As:

Desowen; Tridesilon; Alcon Brand of Desonide; Bayer Brand of Desonide; CS Brand of Desonide; Clay-Park Brand of Desonide; Desocort; Desone; Galderma Brand of Desonide; Locapred; Locatop; Owen Brand of Desonide; Pierre Fabre Brand of Desonide; Tridésonit; Clay Park Brand of Desonide; Prednacinolone; Pregna-1,4-diene-3,20-dione, 11,21-dihydroxy-16,17-((1-methylethylidene)bis(oxy))-, (11beta,16alpha)-

Networked: 43 relevant articles (11 outcomes, 14 trials/studies)

Relationship Network

Drug Context: Research Results

Polycyclic Compounds: 56
- Steroids: 18537
  - Pregnanes: 3
    - Pregnadienes
      - Pregnadienetriols
        Desonide: 43

Experts

1.	Rizer, Ronald L: 3 articles (11/2011 - 07/2011)
2.	Trookman, Nathan S: 3 articles (11/2011 - 07/2011)
3.	Ford, Rosanne O: 3 articles (07/2011 - 07/2011)
4.	Gotz, Vincent: 3 articles (07/2011 - 07/2011)
5.	Kircik, Leon H: 2 articles (07/2011 - 02/2009)
6.	Ho, Elizabeth T: 2 articles (07/2011 - 07/2011)
7.	Hebert, Adelaide A: 2 articles (08/2008 - 02/2007)
8.	Trancik, Ronald J: 2 articles (05/2007 - 02/2007)
9.	Calvarese, Barry: 2 articles (05/2007 - 02/2007)
10.	Basu, Sarmistha: 2 articles (05/2007 - 02/2007)

Related Diseases

1.	Atopic Dermatitis (Atopic Eczema) 08/01/2008 - "A phase II open-label study of the effect of desonide foam 0.05% on the hypothalamic-pituitary-adrenal axis was evaluated in pediatric and adolescent participants with mild-to-moderate atopic dermatitis. " 08/01/2002 - "The aim of this study was to evaluate a mild- to mid-potent topical corticosteroid, desonide 0.05%, on these three parameters in an Australian cohort of patients with facial seborrhoeic or atopic dermatitis. " 03/01/1997 - "Effect of desonide ointment, 0.05%, on the hypothalamic-pituitary-adrenal axis of children with atopic dermatitis." 11/01/2011 - "Desonide hydrogel 0.05%, an effective treatment for mild-to-moderate atopic dermatitis, is United States Food and Drug Administration approved as a treatment for patients as young as three months of age. " 11/01/2011 - "The objective of this clinical noninferiority study was to compare the efficacy of desonide hydrogel 0.05% with desonide ointment 0.05%, the clinical standard for the treatment of mild-to-moderate atopic dermatitis. "
2.	Skin Diseases 07/01/2004 - "Desonide (as a cream, ointment, or lotion formulation) is widely used for the treatment of steroid-responsive dermatoses. " 09/01/2004 - "Desonide 0.05% is a safe and effective low-potency corticosteroid for the treatment of mild to moderate dermatoses in Indian patients. " 09/01/2004 - "Efficacy of desonide 0.05% cream and lotion in steroid-responsive dermatoses in Indian patients: a post-marketing surveillance study." 07/01/2008 - "Desonide is a low-potency topical corticosteroid that has been used for decades in the treatment of steroid-responsive dermatoses. " 05/01/2007 - "Desonide, a low potency corticosteroid, has been used widely as a topical treatment for inflammatory dermatoses for over 30 years. "
3.	Hypersensitivity (Allergy) 07/01/2002 - "Desonide has a significant therapeutic effect on both the induced conjunctival early- and late-allergic reaction and in active SAC. " 07/01/2002 - "To study the safety and efficacy of the topical corticosteroid, desonide 0.25% ophthalmic solution, for inhibition of the clinical allergic reaction induced by conjunctival provocation (CPT) and for the treatment of seasonal allergic conjunctivitis (SAC). " 09/01/1978 - "Phenylbutazone, cyclophosphamide and prednacinolone acetonide, administered around the period of challenge reduced the exudate of pleurisy due to Bordetella pertussis hypersensitivity in the rat. " 09/01/1978 - "Action of phenylbutazone, cyclophosphamide and prednacinolone on pleurisy due to Bordetella pertussis hypersensitivity in the rat." 01/01/1984 - "The actions of F 1865 (ethyl 4' methoxy 4 phenyl thiazolyl 2 oxamate), an inhibitor of the release of histamine from mast cell, desonide, a corticosteroid, mepyramine maleate, an anti-H1 antihistaminic, and disodium cromoglycate were compared after cutaneous application in various experimental models of allergy and inflammation. "
4.	Allergic Conjunctivitis (Giant Papillary Conjunctivitis) 07/01/2002 - "Efficacy and safety of desonide phosphate for the treatment of allergic conjunctivitis." 07/01/2002 - "To study the safety and efficacy of the topical corticosteroid, desonide 0.25% ophthalmic solution, for inhibition of the clinical allergic reaction induced by conjunctival provocation (CPT) and for the treatment of seasonal allergic conjunctivitis (SAC). " 10/01/2004 - "Research developments in ocular allergy summarized in this article include the following findings: (1) ocular epithelial cells play a role in inflammation; (2) respiratory syncytial virus is a pathogen in allergic conjunctivitis; (3) transglutaminase inhibitors reverse allergic related inflammation; (4) eosinophils and neutrophils both play a role in ocular allergy; (5) eotaxin-1 and eotaxin-2 play a role in eosinophilic recruitment; and (6) loteprednol etabonate, desonide phosphate, and cyclosporine have been shown to be effective and safe in the treatment of ocular allergy. "
5.	Inflammation 06/01/2013 - "The aim of this study was to investigate the anti-inflammatory effects of TLC-Ag dressings in a model of chronic skin inflammation induced by repeated application of 12-O-tetradecanoylphorbol-13-acetate to the skin of hairless mice, in comparison with TLC dressing, Silcryst nanocrystalline dressing, desonide cream 0.05%, a corticoid cream used as positive control, and gauze. " 06/01/2013 - "TLC-Ag reduced significantly the microscopic score of chronic skin inflammation in comparison with TLC dressing and gauze, similarly to Silcryst nanocrystalline dressing but significantly less than desonide cream. " 06/01/2013 - "TLC-Ag reduced significantly the macroscopic score of chronic skin inflammation from day 10 in comparison with gauze and TLC dressing, similarly to Silcryst nanocrystalline dressing and desonide cream, which presented the best anti-inflammatory effects. " 02/01/2013 - "MLE formulations did not affect the anti-inflammatory activity of the desonide in phobol ester-induced skin inflammation model, compared with conventional formulations. " 12/01/1982 - "Hydrocortisone reduced the two types of inflammation by the same amount, while desonide had more effect on the delayed hypersensitivity reaction. "

Related Drugs and Biologics

1.	Hydrogel
2.	Hydrocortisone (Cortisol)
3.	Cosmetics
4.	Niacinamide (Nicotinamide)
5.	Fluorometholone (FML)
6.	Emulsions
7.	hydrocortisone-17-butyrate (Locoid)
8.	Chemokine CCL24
9.	Chemokine CCL11
10.	Cyclosporine (Ciclosporin)

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Oral Administration